<DOC>
	<DOC>NCT00584948</DOC>
	<brief_summary>The purpose of this study is to determine if memantine is effective in treating symptoms of Fragile X-associated Tremor Ataxia Syndrome.</brief_summary>
	<brief_title>Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Fragile X premutation carrier (CGG repeat 55200)with neurological symptoms; Clinical FXTAS Stage 15 Previous reaction to memantine</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FXTAS, Fragile X Premutation</keyword>
</DOC>